胰腺癌被动碳离子放疗中骨匹配与肿瘤匹配的每日剂量鲁棒性比较
本研究基于8例胰腺癌患者治疗后的95套每日CT图像,评估被动碳离子放疗中骨匹配与肿瘤匹配对分次间解剖变化的累积剂量鲁棒性。结果显示肿瘤匹配的靶区覆盖优于骨匹配,但部分病例仍不足,需进一步技术改进。
要点
- 肿瘤匹配的CTV和GTV累积V95%均高于骨匹配,且与计划值无显著差异(CTV除外)。
- 骨匹配下CTV累积V95%中位数仅80.5%,显著低于计划值。
- 肿瘤匹配仍不能保证所有病例靶区覆盖充足,需技术改进。
核心结论
- 推荐肿瘤匹配而非骨匹配,因其可获得更高的靶区剂量覆盖,但部分病例仍不足。
研究设计与样本
- 前瞻性研究,纳入8例胰腺癌患者,使用治疗后采集的95套每日CT图像,分别按骨匹配和肿瘤匹配位置重算剂量分布,并采用可变形图像配准计算累积剂量。
- 处方剂量为55.2 Gy(RBE),分12次。
主要发现
- CTV V95%中位数(范围):计划为91.9%(86.1-100.0),骨匹配累积为80.5%(56.1-90.6),肿瘤匹配累积为86.4%(72.5-96.5)。
- GTV V95%中位数(范围):计划为98.0%(85.7-100.0),骨匹配累积为93.3%(65.7-99.9),肿瘤匹配累积为96.2%(84.8-100.0)。
- 除计划与肿瘤匹配外,其余所有组合间靶区V95%均有显著差异。
- 胃D2cc中位数(范围):计划36.0 Gy(RBE)(16.9-43.4),骨匹配36.7 Gy(RBE)(17.9-45.0),肿瘤匹配35.2 Gy(RBE)(16.8-43.5)。
- 十二指肠D2cc中位数(范围):计划25.2 Gy(RBE)(21.3-40.3),骨匹配30.1 Gy(RBE)(23.3-48.6),肿瘤匹配28.3 Gy(RBE)(20.4-50.6);仅计划与骨匹配间有显著差异。
关键数值与推荐
- 靶区评估指标为CTV和GTV的V95(%),危及器官评估指标为胃和十二指肠的D2cc(Gy(RBE))。
- 处方剂量55.2 Gy(RBE)/12次。
临床怎么用
- 胰腺癌被动碳离子放疗中应优先考虑肿瘤匹配以改善靶区覆盖。
- 即使采用肿瘤匹配,仍需关注部分病例靶区覆盖不足的风险。
局限性
- 样本量较小(8例患者),可能影响结论的普适性。
- 研究为被动碳离子放疗,结论是否适用于主动扫描等其它技术尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We aimed to assess the robustness of accumulated dose distributions for inter-fractional changes in passive carbon-ion radiotherapy for pancreatic cancer. METHODS: Ninety-five daily CT image sets acquired after the treatment of eight patients with pancreatic cancer were used in this prospective study. Dose distributions with treatment beam fields were recalculated for bone matching (BM) and tumor matching (TM) positions on all daily CT images, the accumulated doses being calculated using deformable image registration methods. The prescribed dose was 55.2 Gy (relative biological effectiveness [RBE]) in 12 fractions. Dose volume parameters of V95 (%) for CTV and GTV, and D2cc (Gy(RBE)) for the stomach and duodenum were evaluated. RESULTS: The medians (range) of CTV V95 (%) were 91.9 (86.1-100.0), 80.5 (56.1-90.6), and 86.4 (72.5-96.5) for the Plan, accumulated with BM and TM, respectively; GTV values (%) were 98.0 (85.7-100.0), 93.3 (65.7-99.9), and 96.2 (84.8-100.0), respectively. There were significant differences between all combinations apart from the Plan and TM for both targets. The values of stomach D2cc (Gy(RBE)) were 36.0 (16.9-43.4), 36.7 (17.9-45.0), and 35.2 (16.8-43.5), respectively; duodenum values (Gy(RBE)) were 25.2 (21.3-40.3), 30.1 (23.3-48.6), and 28.3 (20.4-50.6), respectively. There was a significant difference between the Plan and BM for duodenum only. CONCLUSIONS: TM is recommended over BM because it can achieve higher target dose coverage than BM. Nevertheless, it is not enough in some cases. Further technical improvements are necessary to improve the target dose coverage.
引用
- Kubota Y, Okamoto M, Shiba S, et al. Robustness of daily dose for each beam angle and accumulated dose for inter-fractional anatomical changes in passive carbon-ion radiotherapy for pancreatic cancer: Bone matching versus tumor matching. Radiother Oncol. 2021. PMID: 33515667. doi:10.1016/j.radonc.2021.01.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。